Financial Accountant

COMPASS Pathways; City of Westminster; On-site; GBP 60,000 - 80,000; Full time

Job summary

A biotechnology company in the UK is seeking a Financial Accountant to support day-to-day accounting operations and ensure the integrity of financial records. The role includes month-end close activities, financial reporting under US GAAP and IFRS, and maintaining financial controls compliant with SOX. Candidates should have a professional accounting qualification and excellent analytical skills. This position offers a high-growth environment focused on innovation in mental health treatments.

Qualifications

• Strong academic background with a recognised professional accounting qualification (ACA, ACCA, or CA).
• Excellent technical accounting knowledge with experience in US GAAP and IFRS.
• Proven ability to work autonomously and take ownership of deliverables.
• Strong analytical and problem-solving skills with a keen attention to detail.
• Effective communication and interpersonal skills, with the ability to collaborate across time zones.

Responsibilities

• Responsible for month-end close activities including balance sheet reconciliations and journal postings.
• Support the preparation of quarterly and annual reporting under US GAAP.
• Assist with accounting and reporting for share-based payments and lease obligations.
• Prepare monthly US GAAP management reporting and annual IFRS statutory financial statements.
• Support tax compliance processes across UK and US jurisdictions.

Skills

Technical accounting knowledge

Analytical and problem-solving skills

Effective communication

Strong academic background

Autonomous work capability

Education

Recognised professional accounting qualification (ACA, ACCA, or CA)

Job description

The Financial Accountant supports day‑to‑day accounting operations, ensuring the accuracy and integrity of financial records and reporting. This hands‑on, technically focused role maintains balance sheet accounts and supports the Director, External Reporting and Senior Director, Controller with consolidated financial reporting and disclosure requirements across UK and US operations.

Responsibilities

• Responsible for month‑end close activities, including balance sheet reconciliations, journal postings (accruals, intercompany transactions, prepayments), and analytical reviews.
• Support the preparation of quarterly (10‑Q) and annual (10‑K) reporting under US GAAP, including audit schedules and documentation.
• Assist with accounting and reporting for share‑based payments, lease obligations, and deferred tax calculations.
• Prepare monthly US GAAP management reporting and annual IFRS statutory financial statements.
• Support tax compliance processes across UK and US jurisdictions.
• Contribute to the design, implementation, and maintenance of financial controls and processes, ensuring compliance with SOX requirements.

Qualifications

• Strong academic background, with a recognised professional accounting qualification (ACA, ACCA, or CA).
• Excellent technical accounting knowledge with experience in US GAAP and IFRS.
• Proven ability to work autonomously and take ownership of deliverables.
• Strong analytical and problem‑solving skills with a keen attention to detail.
• Effective communication and interpersonal skills, with the ability to collaborate across time zones and functions.
• Resilient, adaptable, and comfortable operating within a high‑growth, organisation.
• Alignment with the company's values and commitment to operational excellence.

About Compass Pathways

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence‑based innovation in mental health. The Company is headquartered in London, UK, with offices in New York City in the US.

We focus on developing novel treatments that have the potential to improve the lives of those who are suffering with mental health conditions and who are not helped by current treatments.

We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment‑resistant depression (TRD) due to the pressing unmet need in this area. We are currently in phase 3 for TRD, have completed phase 2 studies for both post‑traumatic stress disorder (PTSD) and anorexia nervosa and are planning a further late‑stage study in PTSD. We envision a world where mental health means not just the absence of illness but the ability to thrive. - Compass Pathways.